ERADICATION THERAPY OF HELICOBACTER PYLORI FOR LOW-GRADE MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMAS OF THE STOMACH
Summary. The purpose of this study was to clarify the clinical features and outcomes of eradication therapy of Helicobacter pylori in low-grade mucosa-associated lymphoid tissue lymphomas of the stomach. Clinical features, including age, sex, tumor size, and endoscopic appearance and outcome, were evaluated. Ten patients were treated with proton-pomp inhibitor-based Helicobacter pylori eradication therapy for 1 or 2 weeks, and followed by endoscopic examinations with biopsy sampling. Helicobacter pylori infection was observed in 9 of 10 (90%) cases. After Helicobacter pylori eradication, patients were observed for a median of 19 months (range, 4–49 months). Seven patients showed complete regression, 2 showed partial regression and 1 showed no change in the lymphoma. One patient, who was originally Helicobacter pylori-negative, had a local relapse 16 months after eradication. No association was found between any clinical features and outcome. This study shows that the eradication of Helicobacter pylori causes regression of low-grade mucosa-associated lymphoid tissue lymphomas of the stomach, and that Helicobacter pylori eradication treatment should be given for the lymphomas as first-line therapy. However, the clinical features did not seem to be useful for predicting tumors that would or would not respond to the eradication therapy.
No Comments » Add comments